

Amendments to the Claims

The following Listing of Claims will replace all prior versions and listings of claims in the above-referenced application.


Listing of Claims:

Claims 1-147. (Canceled)

148. (Currently Amended) The pharmaceutical composition of claim ⁹~~171~~ [144], wherein the therapeutically effective amount is an amount sufficient to deliver about 0.01 mg to about 0.6 mg compound per kg body weight.

149. (Canceled)

150. (Currently Amended) A method of treating cancer in a subject comprising:
administering to the subject in need thereof an average daily dose of a compound having the structure:



wherein R is methyl;[,] and
a pharmaceutically acceptable carrier selected from the group consisting of glycols, oils,
and alcohols.

wherein the amount of the compound in the carrier is sufficient for the composition to deliver to the subject between about 0.001 mg and about 0.6 mg compound per kilogram of the subject's body weight [that is between about 0.001 and 0.6 mg of compound per kilogram of the subject's body weight].

151. (Canceled)

152. (Canceled)

153. (Canceled)

✓ 154. (Previously presented) The method of claim ~~150~~¹, wherein the average daily dose is within the range of about 0.01 mg to about 0.6 mg compound per kg body weight.

155. (Canceled)

156. (Canceled)

157. (Canceled)

158. (Canceled)

159. (Canceled)

160. (Canceled)

✓ 161. (Currently Amended) The method of claim ~~150~~¹ [or claim 158], wherein the step of administering comprises administering individual doses not more frequently than once daily.

✗ 162. (Currently Amended) The method of claim ~~150~~¹ [or claim 158], wherein the step of administering comprises interrupting individual dose administrations with at least one day of

Page 3 of 6

USSN 09/874,514
3609791_1

Attorney's Docket No.: 2003080-0082
Client Ref. No.: SK-744-US/CON3

rest.

5 163. (Currently Amended) The method of claim 150 [or claim 158], wherein the step of administering comprises interrupting individual dose administrations with at least three days of rest.

6 164. (Currently Amended) The method of claim 150 [or claim 158], wherein the step of administering comprises administering over a period of at least about 6 days.

7 165. (Currently Amended) The method of claim 150 [or claim 158], wherein the step of administering comprises administering to an animal that has a multidrug resistant tumor.

8 166. (Currently Amended) The method of claim 150 [or claim 158], wherein the step of administering according to a schedule sufficient to achieve at least about 16% tumor inhibition.


11 167. (Currently Amended) The composition of claim 171 [144], wherein the composition is formulated for parenteral delivery.

12 168. (Currently Amended) The composition of claim 171 [144], wherein the composition is formulated for oral delivery.

13 169. (Currently Amended) The composition of claim 171 [144], wherein the composition comprises an emulsion.

14 170. (Currently Amended) The composition of claim 171 [144], wherein the composition comprises an aqueous suspension.

9 171. (New) A pharmaceutical composition for delivering a therapeutically effective amount of a compound to a mammal, the pharmaceutical composition comprising:
an amount of a compound having the structure:



wherein R is methyl; and

a pharmaceutically acceptable carrier selected from the group consisting of glycols, oils, and alcohols,
wherein the amount of the compound in the carrier is sufficient for the composition to deliver to the mammal between about 0.001 mg and about 0.6 mg compound per kg body weight.